CHAM
OCUL icon

Clear Harbor Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Clear Harbor Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,900
Closed -$47K – 564
2019
Q4 		$47K Sell
11,900
-600
-5% -$2.09K 0.01% 410
2019
Q3 		$38K Buy
+12,500
New +$55.9K 0.01% 254

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clear Harbor Asset Management's OCUL Position: Q1 2020 in Review

Clear Harbor Asset Management sold out of Ocular Therapeutix (OCUL) in Q1 2020, closing a stake of 11,900 shares — an estimated $47K sold.

Clear Harbor Asset Management first reported a position in OCUL in Q3 2019 and held it in 2 quarters. The position peaked at $47K in Q4 2019. 90 funds tracked by Wall St. Rank hold OCUL as of Q1 2020.

  • Clear Harbor Asset Management reported no remaining Ocular Therapeutix position as of Q1 2020 after selling out during the quarter.
  • Clear Harbor Asset Management sold 11,900 Ocular Therapeutix shares in Q1 2020, an estimated $47K.
  • Clear Harbor Asset Management first reported a position in Ocular Therapeutix in Q3 2019 and held it in 2 quarters.
  • Clear Harbor Asset Management's Ocular Therapeutix position peaked at $47K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2020.

Based on Clear Harbor Asset Management's 13F filing for Q1 2020, filed 8 May 2020.